Biologic Therapeutics
Our in silico analyses rely on a unique multi-step process that produces a more accurate assessment of immunogenicity, including a T cell epitope characterization process that surpasses conventional epitope mapping by considering regional immunogenicity, regulatory epitope content and cross-conservation with the human proteome, or “humanness”. Our approach consistently leads to more accurate results, therefore better reducing the risk of programs that could otherwise be destined for failure in the clinic.
Peptide, protein, fusion protein, & scaffold protein therapeutics.
Monoclonal, bispecific, multi-specific, single domain antibodies & other antibody-based constructs
Gene & cell therapies (i.e. CAR-Ts, vectors, payloads)
Vaccines
EpiVax’s vaccine services offer an unparalleled combination of advanced immunoinformatics and expertise in T cell epitope-driven immunity, making them indispensable to vaccine developers. Over the past 25 years, EpiVax has honed a suite of proprietary tools that streamline the design and optimization of vaccines by enabling precise prediction and selection of immunogenic components. These tools are essential for developing vaccines that are not only safer and more effective but also tailored to combat emerging infectious diseases, biothreats, and cancer. By leveraging EpiVax’s capabilities, vaccine developers can accelerate their efforts to deliver next-generation vaccines that provide stronger, long-lasting protection.